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Summary
Background The early detection of medullary thyroid carci-
noma (MTC) can improve patient prognosis, because histologi-
cal stage and patient age at diagnosis are highly relevant
prognostic factors. As a consequence, delay in the diagnosis and/
or incomplete surgical treatment should correlate with a poorer
prognosis for patients. Few papers have evaluated the specific
capability of fine-needle aspiration cytology (FNAC) to detect
MTC, and small series have been reported. This study conducts
a meta-analysis of published data on the diagnostic performance
of FNAC in MTC to provide more robust estimates.
Research Design and Methods A comprehensive computer
literature search of the PubMed/MEDLINE, Embase and Scopus
databases was conducted by searching for the terms ‘medullary
thyroid’ AND ‘cytology’, ‘FNA’, ‘FNAB’, ‘FNAC’, ‘fine needle’ or
‘fine-needle’. The search was updated until 21 March 2014, and
no language restrictions were used.
Results Fifteen relevant studies and 641 MTC lesions that had
undergone FNAC were included. The detection rate (DR) of
FNAC in patients with MTC (diagnosed as ‘MTC’ or ‘suspicious
for MTC’) on a per lesion-based analysis ranged from 125% to
882%, with a pooled estimate of 564% (95% CI: 526–601%).
The included studies were statistically heterogeneous in their
estimates of DR (I-square >50%). Egger’s regression intercept
for DR pooling was 003 (95% CI: 31 to 32, P = 09). The
study that reported the largest MTC series had a DR of 45%.
Data on immunohistochemistry for calcitonin in diagnosing
MTC were inconsistent for the meta-analysis.
Conclusions The presented meta-analysis demonstrates that
FNAC is able to detect approximately one-half of MTC lesions.
These findings suggest that other techniques may be needed in
combination with FNAC to diagnose MTC and avoid false nega-
tive results.
(Received 15 June 2014; returned for revision 8 July 2014; finally
revised 10 July 2014; accepted 16 July 2014)
Introduction
Medullary thyroid carcinoma (MTC) accounts for approxi-
mately 5% of thyroid malignancies.1 MTC is a well-differenti-
ated neuroendocrine carcinoma that arises from thyroid C-cells.
It occurs as a sporadic cancer in approximately 80% of cases
and is part of autosomal dominant genetic familial disorders in
the remaining ones.1 Generally, MTC has an aggressive behav-
iour, being responsible for 8% to 13% of total thyroid cancer
deaths and correlating with a 5-year survival rate of 70%.2,3 The
early detection of MTC can improve patient prognosis, because
histological stage and patient age at diagnosis are highly relevant
factors. As a consequence, delay in the diagnosis and/or incom-
plete surgical treatment should correlate with a poorer prognosis
for patients.4,5
Since its first demonstration, the diagnosis of MTC has repre-
sented a major challenge in clinical practice. In fact, while fine-
needle aspiration cytology (FNAC) is a reliable diagnostic tool
in the assessment of thyroid nodules, cytologic examination has
several pitfalls related to MTC.6,7 Moreover, the routine
measurement of serum calcitonin in all patients with nodular
thyroid disease is still a matter of debate,1,5 and the application
of ultrasonography lacks specificity when diagnosing these
cancers.6,8,9 Owing to these limitations, a significant number of
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MTCs are not recognized until after initial thyroid surgery, with
the consequent risk of an incomplete therapeutic approach.
Overall, few large series have evaluated the effectiveness of
cytology to detect MTC and only a small number of MTC series
have been reported. Thus, our study conducts a meta-analysis of
published data focusing on the diagnostic performance of FNAC
to detect MTC to provide more robust estimates on this topic.
Materials and methods
Search strategy
Initially, we searched studies that have evaluated the accuracy of
cytology for MTC. A comprehensive computer literature search
of the PubMed/MEDLINE, Embase and Scopus databases was
conducted to find published articles on this topic. The search
algorithm was based on combinations of the following terms: A)
‘medullary thyroid’ AND B) ‘cytology’, ‘FNA’, ‘FNAB’, ‘FNAC’,
‘fine needle’ or ‘fine-needle’. A beginning date limit was not
used and the search was updated until 21 March 2014 without
language restrictions. To identify additional studies and expand
our search, the references of the retrieved articles were also
screened.
Study selection
Studies or subsets in studies that report data on the detection
rate (DR) of MTC by FNAC were eligible for inclusion. The
main exclusion criteria were (i) articles not within the field of
interest of this review, (ii) review articles, editorials, letters or
comments, and (iii) articles that did not provide clear study
characteristics or reports that had overlapping patient data. Case
reports were also excluded. Two investigators (PT, GT) indepen-
dently reviewed the titles and abstracts of the retrieved articles,
applying the inclusion and exclusion criteria previously
described. Then, the same two researchers independently
reviewed the full-text of the remaining articles to determine their
inclusion. Disagreements were resolved in a consensus meeting
involving a third author (LG).
Data extraction
For each included study, information was abstracted concerning
study data (authors, journals, year of publication and country of
origin). The number of patients evaluated, number of histologi-
cally proved MTCs and the DR of FNAC for MTC were also
extracted. Moreover, the results of FNAC for each lesion were
provided.
Statistical analysis
The DR of FNAC in patients with MTC was calculated from
each article on a per lesion-based analysis using this formula:
DR = TP/(TP + FN), where TP were ‘MTC’ or ‘suspicious for
MTC’ FNAC and FN were false negative (non-MTC) FNAC
results. A random effects model was then used statistically pool-
ing the data. Pooled data are presented with 95% confidence
intervals (95% CI). An I-square index was used to test for heter-
ogeneity among the studies (significant heterogeneity was
defined as having an I-square value >50%). Finally, to evaluate
publication bias, funnel plots and Egger’s regression intercepts10
were used. Statistical analyses were performed using StatsDirect
statistical software (StatsDirect Ltd; Altrincham, UK).
Results
The comprehensive computer literature search for MTC and
FNAC (see Materials and methods) revealed 3551 articles. The
Fig. 1 Flowchart of the search for eligible studies
on the detection rate of FNAC in patients with
MTC.
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review of the titles and abstracts of these papers excluded many
records according to the above-mentioned criteria. Ultimately,
17 articles were selected and their full-text versions retrieved.11–
27 Another additional study was found by screening the refer-
ences of these papers.28 However, one study was excluded
because of unclear results (the MTC diagnoses were not specifi-
cally detailed between the malignant FNAC),25 and two other
papers were removed from the sample owing to overlapping
data.26,27 Altogether, 15 studies were included in our meta-
analysis 11–24,28 (Fig. 1). The main characteristics of these studies
are summarized in Table 1.
Overall, the sampled studies included 641 MTC lesions that
had undergone FNAC. Approximately half (360/641) of these
were assessed by FNAC as ‘MTC’ or ‘suspicious for MTC’. The
DR of FNAC in patients with MTC on a per lesion-based analy-
sis ranged from 125% to 882%, with a pooled estimate of
Table 1. Characteristics of the 15 studies included in the meta-analysis
First author Year Country Aim of the study
MTC lesions undergone FNAC
n MTC diagnosed (%)
Elisei11 2004 Italy To evaluate routine serum calcitonin measurement 44 20 (455)
Bugalho12 2005 Portugal To assess the accuracy of FNAC in MTC 67 42 (627)
Chang13 2005 China–Taiwan To review MTC cases 34 30 (882)
Vierhapper14 2005 Austria To evaluate routine serum calcitonin measurement 13 2 (154)
Boi15 2007 Italy To assess diagnostic accuracy of FNA-calcitonin 21 13 (619)
Kudo16 2007 Japan To assess diagnostic accuracy of FNA-calcitonin 5 4 (800)
Seningen17 2010 USA To review FNAC diagnosis 27 21 (778)
Kaushal 18 2011 India To review MTC cases 78 54 (692)
Colombo28 2012 Italy To evaluate calcium stimulation test for calcitonin 7 2 (286)
Diazzi19 2013 Italy To assess diagnostic accuracy of FNA-calcitonin 8 1 (125)
Essig20 2013 USA–Italy–Greece–
Brazil–UK–Belgium
To assess the diagnostic value of FNAC 245 112 (457)
Jo21 2013 USA To review FNAC diagnosis 16 13 (813)
Trimboli22 2014 Italy–Switzerland To assess accuracy of FNA-calcitonin and FNAC 37 21 (568)
Samulski23 2014 USA To review MTC cases 33 23 (697)
Boschin 24 2014 Italy To evaluate pentagastrin stimulation test for calcitonin 6 2 (333)
Overall 641 360
Fig. 2 Plot of individual studies and pooled
detection rate of FNAC in patients with MTC,
including 95% confidence intervals.
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564% (95% CI: 526–601%) (Fig. 2). The included studies were
statistically heterogeneous in their estimates of DR (I-square
>50%). In particular, those studies that included smaller series
reported lower FNAC sensitivity. The study that reported the
largest MTC series20 had a DR of 45%. The cytologic reports of
MTC not classified as ‘MTC’ nor ‘suspicious for MTC’ are
described in Table 2. Excluding the study of Essig. et al.20 which
is a collection of patients selected from multiple centres, we
found a pooled DR of 588% (95% CI: 484–689%), which is
quite similar to the overall DR we reported including all the
studies.
The funnel plot that was used to assess possible publication
bias is shown in Fig. 3. Egger’s regression intercept for DR pool-
ing was 003 (95% CI: 31 to 32, P = 09). Only two
papers18,22 described the application of immunohistochemistry
for calcitonin in diagnosing MTC, and data were inconsistent
for the purposes of meta-analysis. Similarly, data about nodule
size were poor to be meta-analysed. No significant difference
was recorded regarding familial or sporadic MTC forms, patient
gender, patient age or lesion size.
Discussion
In this study, we included 15 articles published between 2004
and 2014 that reported the capability of cytology to detect MTC.
The main result from this meta-analysis is that 56% of histologi-
cally proven MTCs are correctly detected by cytologic evalua-
tion, while the remaining MTCs are reported by FNAC as
Table 2. Cytologic reports of MTC not classified as ‘MTC’ nor ‘suspicious for MTC’
First author Year n
Cytologic Classification
Other malignancies Indeterminate Benign Not adequate
Elisei11 2004 24/44 9 – 11 4
Bugalho12 2005 25/67 14 5 6 –
Chang13 2005 4/34 1 3 – –
Vierhapper14 2005 11/13 – – 11*
Boi15 2007 8/21 – – 8 –
Kudo16 2007 1/5 – – – 1
Seningen17 2010 6/27 1 2 1 2
Kaushal18 2011 24/78 23 1 – –
Colombo28 2012 5/7 – 2 1 2
Diazzi19 2013 7/8 Cytologic reports not available
Essig20 2013 133/245 39 64 15 15
Jo21 2013 3/16 – 2 1 –
Trimboli22 2014 16/37 – 3 6 7
Samulski23 2014 10/33 – 10 – –
Boschin24 2014 4/6 – 4 – –
*The authors did not detail benign and not adequate FNAC reports.
Fig. 3 Funnel plot for publication bias assessment.
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benign, indeterminate, nondiagnostic or as other types of
neoplasms. Elisei et al.11 reported that 20/44 MTCs (45%
sensitivity) were cytologically suspicious for this cancer. Later,
Bugalho et al.12 recorded a detection rate of 63% (42/67 cases)
by FNAC. More recently, a large multicentre study by Essig
et al.20 collected 313 MTCs from 12 institutions over 29 years.
Of these, 245 underwent FNAC and 112 (457%) were correctly
read as MTC or as possible MTC. Overall, in the fifteen papers
sampled in this study, about fifty per cent of MTC were assessed
as other malignancies, benign or nondiagnostic. Table 2 presents
these data in more detail. An important cause of a false negative
FNAC diagnosis was misinterpreting MTC as other tumours,
especially as a H€urthle cell neoplasm or follicular neoplasm.7
Two studies with different designs and aims must be men-
tioned here. Papaparaskeva et al.29 retrospectively reviewed the
aspirate reading of ‘medullary carcinoma of the thyroid’ in
their department between 1977 and 1999; 81 of 91 cytologies
reading for MTC were histologically confirmed as MTC and 10
of 91 were false positives, with a consequent positive predictive
value of 89%. Similar results were reported by Forrest et al.30
over the period 1976–1997, namely a positive predictive value
of 81% (17/21). Based on these interesting findings, there is
also a small false positive rate for MTC that needs to be taken
into account.
Other techniques were reported as having been used to detect
MTC in FNAC samples. The use of immunohistochemistry for
calcitonin was described in only two papers included in the
meta-analysis.18,22 In both articles, the sensitivity of FNAC sig-
nificantly increased up to 70%18 and 90%22 when immunohisto-
chemical evaluation was added. More recently, the diagnosis of
MTC has been improved by measurement of calcitonin in nee-
dle washout fluids after aspiration (FNA-calcitonin). As the
firsts, two papers showed high accuracy of FNA-calcitonin in
detecting MTC15,16; after, a multicentre study indicated that
FNA-calcitonin has higher sensitivity than cytology in diagnos-
ing MTC.22 In clinical practice, the use of FNA-calcitonin and
immunohistochemistry for calcitonin should be useful in those
patients having high serum calcitonin value before nodule aspi-
ration. Serum calcitonin is the main diagnostic tool to detect
MTC in patients with thyroid nodules.1 Work by Elisei et al.11
suggested that serum calcitonin has a higher sensitivity than
FNAC for detecting MTC. As an extension of these data, in the
series by Bugalho et al.,12 cytology was positive in only 74% of
those patients with elevated serum calcitonin. These results were
corroborated by subsequent studies.1,5 Even if the sensitivity for
MTC of serum calcitonin has been reported as high, its use as a
routine test in patients with thyroid nodules is controversial.
Examining serum calcitonin in patients eligible for thyroid nod-
ule biopsy would likely contribute to improved detection of
MTC,31 but this approach is not included in current guide-
lines.1,5 Finally, other potential serum diagnostic markers (i.e.
CEA, procalcitonin or other neuroendocrine molecules) of MTC
have been reported, but their role in indentifying this cancer
deserves further studies.6
A possible limitation of our meta-analysis could be the heter-
ogeneity between the included studies. Heterogeneity between
studies may represent a potential source of bias in a meta-analy-
sis. This heterogeneity is likely to arise through diversity in
methodological aspects among studies. The baseline differences
among the patients in the included studies and study quality
may contribute to the heterogeneity of the results, too. In our
pooled analysis, for example, the included studies were statisti-
cally heterogeneous in their estimate of the DR (I-square >50%).
However, this heterogeneity has been accounted for using a ran-
dom effects model.
Publication bias is another major concern in all meta-analyses,
as studies that report significant findings are more likely to be
published than those reporting nonsignificant results. Indeed,
small-sized early studies often reported a positive relationship
that subsequent larger studies failed to replicate. We assessed
publication bias in our meta-analysis using qualitative and quan-
titative methods (Egger’s regression method). Our funnel plots
showed mild asymmetry for DR pooling, but Egger’s regression
method did not show a significant publication bias.
In conclusion, our meta-analysis demonstrates that FNAC is
able to accurately detect only approximately one-half of histo-
logically proven MTC lesions. Based on these findings, other
techniques and specific approaches to patients with thyroid nod-
ules are likely to be needed in combination with FNAC to more
accurately diagnose MTC and avoid false negative results.
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